# Cymbalta (duloxetine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/duloxetine

> Cymbalta (duloxetine), sponsored by ELI LILLY & Co (LLY): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cymbalta (duloxetine) |
| Codes |  |
| Sponsor | ELI LILLY & Co (LLY) https://sec-api.dev/companies/lly/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### April 20, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA021427 SUPPL-52 (Efficacy): submission_status AP, submission_status_date 20200420, review_priority STANDARD; sponsor_name LILLY; product CYMBALTA (DULOXETINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021427%22

### Nov 2026: topline data readout

- Status: scheduled. Date confidence: month.
- First seen 2026-11-05, last confirmed 2026-11-06.
- SEC Form 10-Q (accession 0001104659-26-123635): "Based on the recommendation of the independent statisticians conducting the assessment to slightly increase sample size from the planned 200, we chose to enroll 239 patients to maintain 80+% power, and will have top-line data from the trial available in November of 2026." https://www.sec.gov/Archives/edgar/data/1818844/000110465926123635/dwtx-20260930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-123095): "Top-line results are expected to be announced in November 2026." https://www.sec.gov/Archives/edgar/data/1818844/000110465926123095/dwtx-ex99d1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/duloxetine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cymbalta (duloxetine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/duloxetine

```bibtex
@misc{secapidev_pdufa_duloxetine_20261116,
  title        = {Cymbalta (duloxetine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/duloxetine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_duloxetine_20261116","title":"Cymbalta (duloxetine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/duloxetine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
